

Contract Manufacturing

130 forms and doses | 25 million packages a year | Key therapeutic areas |
Highly potent products up to OEB 5 | EU GMP compliant



TZF POLFA – 200 YEARS OF EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY

200 years of tradition have allowed TZF Polfa to develop a comprehensive pharmaceutical portfolio that continuously evolves to meet patients' changing needs. Building on this legacy, we have established the most advanced high-potency drug manufacturing facility in Central and Eastern Europe. The Center for the Development and Manufacturing of Highly Potent Drugs features two dedicated sterile production lines – including one capable of handling high-potency compounds up to OEB 5 – ensuring maximum safety and product integrity.

Our facility is equipped to produce an extensive variety of forms and dosages, manufacturing over 25 million packages annually across a wide range of strengths and formats. We offer a comprehensive portfolio of pharmaceutical dosage forms.



OUR SPECIALIZATION



Tablets and capsules



Lyophilizates for injectable solutions



Powders for suspension




Injectable solutions and suspensions



Gels and pharmaceutical aerosols



We focus on delivering high-quality generics, ensuring accessible and effective therapies for patients worldwide. Our production encompasses several therapeutical groups, including:



Anti-infectives



Dermatology



Diabetology



Oncology & Rheumatology



Central Nervous System (CNS)



Alimentary Tract & Metabolism



TZF Polfa offers flexible cooperation models tailored to our partners' needs, including:

1

CDMO

2

CMO

3

License In & License Out

4

Distribution agreements



INJECTABLES – DRY POWDERS

Pharmaceutical forms:

- powders for suspension, solution for injection, infusion
- lyophilized powders for suspension, solution for injection, infusion

Primary packaging:

- glass vials (dry powder filling) 20R, 50R, 100R and 200R, flip-off cap
- glass vials (dry powder filling, lyophilisation) 2R, 6R, 10R, 20R, 30R, 50R, flip-off cap

Secondary packaging:

- folding boxes for individual vials

New production facilities:

- availability: IIIQ2028 (lyophilisation)

Estimated annual capacities:

- 2M (lyophilisation) – 15M (filling) vials



INJECTABLES – STERILE SOLUTIONS

Pharmaceutical forms:

- solutions in glass ampoules
- solutions or suspensions in glass cartridges
- solutions in glass vials

Primary packaging:

- ampoules 2 ml and 5 ml
- cartridges 3 ml
- vials 2R, 6R, 10R, 20R, 30R, 50R

Secondary packaging:

- folding boxes for individual vials and for 5 or 10 for ampoules and cartridges

Estimated annual capacities:

- 10M (ampoules); 6M (cartridges)
10M (vials)



INJECTABLES – HIGH-POTENT

(up to OEB 5)

Pharmaceutical forms:

- solutions in glass vials
- solutions in prefilled syringes
- lyophilized powder for injection in vials

Primary packaging:

- PFS 0.5 ml, 1 ml, 5 ml
- vials 2R, 8R, 10R, 30R, 50R

Secondary packaging:

- folding boxes for individual vials/PFS

New production facilities:

- availability: IVQ2027

Estimated annual capacities:

- between 0.6M (lyophilisation)
– 3M (filling) vials or PFS



SOLID ORAL DOSAGE FORMS

Pharmaceutical forms:

- tablets & film coated tablets (sugar, organic solvent); size 5 mm–19 mm
- hard gelatine capsules; size 4–00
- dry powders, granulates for oral suspensions; dose 3–30 g

Secondary packaging:

- folding boxes in different sizes and configurations

Primary packaging:

- blistering Alu-Alu, Alu-PVC, PVdC
- containers and jars (for tablets and capsules)
- bottles (glass, plastic) in different sizes 30–200 ml (for powders and granulates)

Estimated annual capacities:

- 100M (tablets or capsules)
dry powders 0.5M bottles



SEMISOLID DOSAGE FORMS

Pharmaceutical forms:

- gels
- ointments
- pressurized aerosols

Secondary packaging:

- folding boxes for individual tubes and monoblocks

Primary packaging:

- aluminium tubes 5–50 g
- PE tubes 5–15 g
- aluminium monoblocks 35 mm (50–110 ml)

Estimated annual capacities:

- 1M (gels or ointments)
- 2M aerosol cans

Active Pharmaceutical
Ingredients and Intermediates

Estimated annual capacities:
approx. 15 batches

Technological platforms

- synthesis at -10 ÷ 110°C
- crystallization at -10 ÷ 80°C
- vacuum and pressure filtration
- ultrafiltration
- vacuum distillation & drying
- grinding
- batch size 100–1000 l

Other services

- chemical & microbiological analysis
- release by qualified person
- procurement of starting materials
- filling of bottles with nonsterile solutions
- API micronization
- serialization EU, other countries possible





CONTACT US!

Let's discuss how our contract manufacturing services can accelerate your pharmaceutical projects. Get in touch today!

cmo@tzf.pl

TZ **Polfa**

Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
A. Fleminga 2 Street, 03-176 Warsaw, Poland
NIP 5250000564 | REGON 010721743 | KRS 27471

www.tzf.pl

TZF236/26/09/2025

Scan the QR code
to learn more about
our services

